Report error Found 424 Enz. Inhib. hit(s) with all data for entry = 2108
Affinity DataIC50: 1.96nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Affinity DataIC50: 2.03nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Affinity DataIC50: 2.11nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Affinity DataIC50: 2.15nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Affinity DataIC50: 2.24nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Affinity DataIC50: 2.46nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Affinity DataIC50: 2.53nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Affinity DataIC50: 2.56nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Affinity DataIC50: 2.72nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Affinity DataIC50: 2.78nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Affinity DataIC50: 2.80nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Affinity DataIC50: 2.81nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Affinity DataIC50: 3.01nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Affinity DataIC50: 3.04nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Affinity DataIC50: 3.04nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Affinity DataIC50: 3.11nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Affinity DataIC50: 3.13nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Affinity DataIC50: 3.13nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Affinity DataIC50: 3.28nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Affinity DataIC50: 3.33nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Affinity DataIC50: 3.42nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Affinity DataIC50: 3.46nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Affinity DataIC50: 3.49nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Affinity DataIC50: 3.56nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Affinity DataIC50: 3.66nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Affinity DataIC50: 3.76nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Affinity DataIC50: 3.79nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Affinity DataIC50: 3.86nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Affinity DataIC50: 3.87nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Affinity DataIC50: 3.89nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Affinity DataIC50: 3.92nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Affinity DataIC50: 3.93nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Affinity DataIC50: 3.99nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Affinity DataIC50: 4.07nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Affinity DataIC50: 4.07nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Affinity DataIC50: 4.09nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Affinity DataIC50: 4.13nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Affinity DataIC50: 4.16nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Affinity DataIC50: 4.16nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Affinity DataIC50: 4.17nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Affinity DataIC50: 4.19nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Affinity DataIC50: 4.23nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Affinity DataIC50: 4.38nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Affinity DataIC50: 4.38nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Affinity DataIC50: 4.47nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Affinity DataIC50: 4.49nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Affinity DataIC50: 4.52nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Affinity DataIC50: 4.52nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Affinity DataIC50: 4.57nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Affinity DataIC50: 4.57nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
